| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.34 | 1e-10 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.36 | 1e-09 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.2 | 3e-07 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.24 | 1e-05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.28 | 2e-05 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.16 | 4e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-05 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.21 | 6e-05 |